At the pharmacy, you can buy anything from tea kettles to Tylenol. But what if you could buy a rapid HIV test over the counter and test yourself in the privacy of your own home?

Such a test, which experts say could profoundly change attitudes towards HIV diagnosis and how we go about it, is already being made by Bethlehem, Penn.-based OraSure Technologies Inc. The test shows results within 20 minutes: one blue line means HIV negative, two blue lines means HIV positive. Some researchers are excited by the prospect, but others worry that American society isn’t ready for testing without counseling.

This week, an advisory panel to the U.S. Food and Drug Administration unanimously recommended the test to the FDA, which is expected to issue a final decision later this year, and the product could feasibly be on the market within the next two years.  

The technology isn't especially new. A similar OraSure rapid test has been used in clinics since 2004. HIV-1 and HIV-2 induced antibodies are detected from oral fluid, which is collected with a swab and placed in a vial containing a "developer solution." The solution aids the flow of the specimen along a test strip. If the sample contains the antibodies, it will react with substances on the test strip to indicate a positive result.

In recent years, HIV testing has become progressively more accessible. The introduction of rapid oral HIV tests in clinics was followed in 2006 by a new set of guidelines from the U.S. Centers for Disease Control and Prevention, which resulted in an opt-out policy. The CDC recommended that individuals from ages 13 to 64 be tested at least once for HIV in their lifetimes during a routine medical checkup. If patients don’t want the test, they would have to explicitly opt out.

Sixty-five percent of Americans were in favor of this new policy, according to a 2006 survey by the Kaiser Family Foundation.

Alex Carballo-Dieguez, a psychologist who specializes in HIV prevention research at Columbia University, conducted research to find out how and if high-risk groups would use the at-home test. He surveyed a cohort of 60 non-monogamous men who have receptive sex with men and don't use condoms, despite an awareness of the risks.  

Eighty percent of the participants said they would use the test by themselves or mutually with a partner if it were available over the counter. Most participants expressed enthusiasm because the technology didn't interfere with sexual pleasure, the main reason that they shun condoms. Most participants were also aware that a negative result doesn't provide a 100-percent guarantee because of a two-week period after infection, in which antibodies are not produced and therefore not detected.

Carballo-Dieguez doesn't anticipate that the test would change the sexual behavior of people that practice safe sex. "If people use condoms, why would they opt for a technology that is less protective?" he said.

Others disagree.

The introduction of the 20-minute OraSure rapid test into clinics has "already been a concern" for its potential to reduce condom use, according to Sean Philpott, a bioethicist at Union Graduate College in Schenactady, N.Y. Philpott, however, agrees with Carballo-Dieguez that the test would help individuals who don’t use condoms by "giving them additional information so that they can at least practice sex a little safer."

Philpott said that the test could help to routinize HIV testing – that is, encourage people who don't perceive themselves at risk to have routine tests. He thinks that it may provide more testing opportunities for people who would otherwise like to be tested. "I am thinking about situations for men who have sex with men, drug abusers or people who live in rural or conservative areas and don't feel comfortable talking to their physicians," he said.

Despite these positive applications, Philpott still harbors reservations. "HIV stigmatization is still pervasive enough that I think you need a clear counseling component,” he said, “I am all for streamlining the counseling process but there are still situations in which individuals have received a positive result and either spun into clinical depression or committed suicide."